As Chemocentryx INC (CCXI) Shares Rose, Shareholder Bvf INC Decreased by $5.02 Million Its Stake

June 27, 2018 - By Joseph March

ChemoCentryx, Inc. (NASDAQ:CCXI) Corporate LogoDuring 2018 Q1 the big money sentiment decreased to 1. That’s change of 0.30, from 2017Q4’s 1.3. 10 investors sold all, 36 reduced holdings as CCXI ratio dropped. 22 grew holdings while 24 funds amassed holdings. Funds hold 24.22 million shares thus 3.03% more from 2017Q4’s 23.51 million shares. Banque Pictet Cie has invested 0.02% in ChemoCentryx, Inc. (NASDAQ:CCXI). Trexquant Inv Lp invested in 11,574 shs or 0.01% of the stock. Pnc Fin Svcs Group stated it has 219,821 shs or 0% of all its holdings. Voya Invest Management Limited Liability Com reported 12,285 shs. Piermont Mgmt has invested 0.1% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI). Proshare Advsr Llc holds 25,705 shs. Jacobs Levy Equity Mgmt has 15,708 shs. Moreover, Wells Fargo Co Mn has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 52,971 shs. Bridgeway Mngmt has 50,246 shs for 0.01% of their capital. Royal National Bank Of Canada invested in 3 shs or 0% of the stock. Morgan Stanley holds 0% of its capital in ChemoCentryx, Inc. (NASDAQ:CCXI) for 93,203 shs. D E Shaw & owns 352,867 shs. Price T Rowe Associate Md reported 460,141 shs. Fernwood Mngmt Llc holds 0.08% or 10,000 shs in its capital. The Ohio-based Public Employees Retirement Sys Of Ohio has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI).

CCXI registered $6.04 million net activity with 0 insider purchases and 8 sales since May 1, 2018. 92,798 shs were sold by Schall Thomas J., worth $1.19M on Monday, May 21. 50,000 ChemoCentryx, Inc. (NASDAQ:CCXI) shs with value of $550,912 were sold by Cappel Markus J..

In 2018Q1 Securities and Exchange filling is reported Bvf Inc’s holdings in Chemocentryx Inc (CCXI) which was decreased by 5.09%. The company’s stock rose 32.26% while stock markets declined as Bvf Inc sold 386,100 shares. The hedge fund is holding 7.20M shares, compared to the 7.59M from the previous quarter. And the reported value of the health care company is $97.94M for the 2018Q1. For a total of 4.11 million shares it increased its holding in Immune Design Corp (NASDAQ:IMDZ) by 2.64M shares in the quarter, and has risen its stake in Pieris Pharmaceuticals Inc.

ChemoCentryx, Inc. (NASDAQ:CCXI) is awaited to publish earnings on August, 14., according to RTT. The EPS diference is $0.06 or 31.58 % down from last years number. Previous year: $-0.19; Analysts forcast: $-0.25. 31.58 % negative EPS growth is what analysts predict. $-0.19 EPS was published for previous quarter.

Another two news for ChemoCentryx, Inc. (NASDAQ:CCXI) were briefly posted by: on May 30, 2018 with title “ChemoCentryx to Present at Two Upcoming Investor Conferences”. The other‘s article was titled “4 Top-Ranked Nasdaq Stocks That Have Doubled This Year” and posted on June 14, 2018.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

A total of 3 analysts rate ChemoCentryx (NASDAQ:CCXI) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $20 highest and $16 lowest target. The avg target $17.67 is 35.20% above the last ($13.07) price. (NASDAQ:CCXI) has 3 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Tuesday, March 13 the company was maintained by JP Morgan.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: